~~<i id='B7FAE3EB8D'><strike id='B7FAE3EB8D'><tt id='B7FAE3EB8D'><pre id='B7FAE3EB8D'></pre></tt></strike></i>~~

00:00

00:00 00:00 LIVE

buffering

Replay

focus

leisure time

author：leisure time 2025-10-01 17:21:36 - browse：468

Damian Garde of STAT talks with Liisa Bayko of Evercore ISI and Jared Holz of Mizuho at STAT in NYC. — Damian Garde of STAT, left, talked with Liisa Bayko of Evercore ISI and Jared Holz of Mizuho about the GLP-1 weight loss market. Michelle C. Gevint for STAT

NEW YORK — Will the world actually soon spend $100 billion a year on the new obesity medicines?

Plenty of people in pharma and at the banks that invest in it seem to think so. Goldman Sachs, Barclays, BMO Capital Markets and Pfizer have all arrived at the glossy, cut-for-headline number for spending by around 2030.

Yet Jared Holz, a healthcare strategist at Mizuho, is skeptical.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Medicare details structure of new drug price negotiation program
Next article： Stories you might have missed in 2023: health, science, medicine

focus

leisure time

focus

entertainment

knowledge

DarronCummings/APAdviserstotheFoodandDrugAdministrationvoted11-0onMondaytorecommendtheapprovalofadru

WSS

Does Paxlovid work in people vaccinated against Covid

Medical device trials still don't enroll enough women, study finds

5 takeaways from STAT's examination of Zynex Medical

Study: Why relieving medical debt did not improve financial outcomes

Readers discuss the intersection of pregnancy and addiction

Arena BioWorks launches in Cambridge to speed drug discovery

focus

leisure time

focus

Psychedelics group wrestles with new pharma identity

Teladoc has a new CEO, but challenges remain the same

Alkermes shareholders re

Hospital chaplains balance Covid safety with patients’ spiritual needs

23andMe had bad news about my health. I wish a person had delivered it

Readers discuss the intersection of pregnancy and addiction

In age of alternative facts, a scholarly course on calling out crap

Merck to acquire Harpoon Therapeutics for $680 million

The cancer drug shortage isn’t new — and neither are the solutions

Profiling embryos to choose those with higher IQs is almost a reality

focus

Allen Institute goes after foundational questions, CEO Costa says

Hospital chaplains balance Covid safety with patients’ spiritual needs

NIH tests clinical research in primary care with $30 million program

Hospital chaplains balance Covid safety with patients’ spiritual needs

5 takeaways from STAT's examination of Zynex Medical

Teladoc has a new CEO, but challenges remain the same

leisure time

focus

entertainment

knowledge